Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Research & Development of $28.4 million in Q1 2026, up 143.17% quarter-over-quarter from -$65.9 million in Q4 2025, and down 20.38% year-over-year from $35.7 million in Q1 2025.
Vanda Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $28.4 million for Q1 2026.
- In Q1 2026, Research & Development fell 20.38% year-over-year to $28.4 million; the TTM figure through Mar 2026 stood at $7.1 million (down 92.0% YoY), while the FY2025 annual figure was $14.4 million, down 80.65% from the prior year.
- Research & Development came in at $28.4 million for Q1 2026 at Vanda Pharmaceuticals, up from -$65.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $35.7 million in Q1 2025 to a low of -$65.9 million in Q4 2025.
- A 5-year average of $16.5 million and a median of $21.0 million in 2022 frame the typical range for Research & Development.
- On a YoY basis, Research & Development climbed as much as 68.82% in 2025 and fell as far as 431.98% in 2025.
- Vanda Pharmaceuticals' Research & Development stood at $18.5 million in 2022, then soared by 31.89% to $24.3 million in 2023, then fell by 18.48% to $19.8 million in 2024, then plunged by 431.98% to -$65.9 million in 2025, then surged by 143.17% to $28.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $28.4 million, -$65.9 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | 28.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.44 Mn |
| Dec 31, 2025 | -65.87 Mn |
| Sep 30, 2025 | 22.56 Mn |
| Jun 30, 2025 | 21.99 Mn |
| Mar 31, 2025 | 35.71 Mn |
| Dec 31, 2024 | 19.84 Mn |
| Sep 30, 2024 | 16.78 Mn |
| Jun 30, 2024 | 16.66 Mn |
| Mar 31, 2024 | 21.15 Mn |
| Dec 31, 2023 | 24.34 Mn |
| Sep 30, 2023 | 16.60 Mn |
| Jun 30, 2023 | 16.65 Mn |
| Mar 31, 2023 | 19.24 Mn |
| Dec 31, 2022 | 18.45 Mn |
| Sep 30, 2022 | 24.86 Mn |
| Jun 30, 2022 | 21.49 Mn |
| Mar 31, 2022 | 20.97 Mn |
| Dec 31, 2021 | 19.33 Mn |
| Sep 30, 2021 | 19.65 Mn |
| Jun 30, 2021 | 20.25 Mn |
| Mar 31, 2021 | 16.13 Mn |
| Dec 31, 2020 | 350,000.00 |
| Sep 30, 2020 | 12.30 Mn |
| Jun 30, 2020 | 12.90 Mn |
| Mar 31, 2020 | 15.53 Mn |
| Dec 31, 2019 | 13.07 Mn |
| Sep 30, 2019 | 11.35 Mn |
| Jun 30, 2019 | 10.95 Mn |
| Mar 31, 2019 | 13.28 Mn |
| Dec 31, 2018 | 12.92 Mn |
| Sep 30, 2018 | 11.39 Mn |
| Jun 30, 2018 | 9.87 Mn |
| Mar 31, 2018 | 9.42 Mn |
| Dec 31, 2017 | 10.15 Mn |
| Sep 30, 2017 | 10.18 Mn |
| Jun 30, 2017 | 7.65 Mn |
| Mar 31, 2017 | 10.57 Mn |
| Dec 31, 2016 | 7.61 Mn |
| Sep 30, 2016 | 7.29 Mn |
| Jun 30, 2016 | 6.70 Mn |
| Mar 31, 2016 | 7.55 Mn |
| Dec 31, 2015 | 8.75 Mn |
| Sep 30, 2015 | 9.97 Mn |
| Jun 30, 2015 | 5.95 Mn |
| Mar 31, 2015 | 4.48 Mn |
| Dec 31, 2014 | 4.75 Mn |
| Sep 30, 2014 | 3.70 Mn |
| Jun 30, 2014 | 3.51 Mn |
| Mar 31, 2014 | 7.26 Mn |
| Dec 31, 2013 | 6.27 Mn |
| Sep 30, 2013 | 8.02 Mn |
| Jun 30, 2013 | 6.10 Mn |
| Mar 31, 2013 | 8.11 Mn |
| Dec 31, 2012 | 10.94 Mn |
| Sep 30, 2012 | 10.16 Mn |
| Jun 30, 2012 | 12.49 Mn |
| Mar 31, 2012 | 12.18 Mn |
| Dec 31, 2011 | 10.56 Mn |
| Sep 30, 2011 | 8.17 Mn |
| Jun 30, 2011 | 6.00 Mn |
| Mar 31, 2011 | 4.27 Mn |
| Dec 31, 2010 | 3.82 Mn |
| Sep 30, 2010 | 4.07 Mn |
| Jun 30, 2010 | 2.40 Mn |